Description
Product Overview
Cartalax is a short synthetic tripeptide associated with the amino-acid sequence Ala-Glu-Asp, commonly abbreviated as AED. Its defined three-residue structure has been investigated within experimental short-peptide, cellular and gene-expression research models.
Pronoia supplies Cartalax as a 10mg lyophilised research peptide for laboratory research, analytical investigation and controlled experimental use.
Product Specification
Product: Cartalax
Strength: 10mg
Peptide class: Synthetic tripeptide
Form: Lyophilised solid
Sequence: H-Ala-Glu-Asp-OH
Sequence notation: AED
Pronoia minimum purity standard: ≥98%
Storage: Temperature-controlled cold storage
Intended use: Laboratory research only
Quality, Testing & Traceability
Pronoia maintains a structured quality and traceability process across its research catalogue.
- Supplier analytical documentation retained
- Independent third-party laboratory testing
- Minimum accepted purity standard of 98%
- Full batch traceability
- Batch-separated and labelled inventory
- Physical stock reconciled with digital inventory
- Temperature-controlled cold storage
- Certificate of Analysis and Safety Data Sheet maintained for each product
Batch-specific documentation can normally be provided by Pronoia within 24 hours of a documentation request.
Research Context
The AED tripeptide has been investigated in experimental short-peptide research involving cellular differentiation, gene expression and tissue-associated biological models.
Published research involving Ala-Glu-Asp has examined areas including:
- Chondrogenic differentiation and cartilage-associated stem-cell research models
- Gene-expression responses in human mesenchymal stem-cell cultures
- Cellular ageing models and peptide-mediated regulatory responses
- Short-peptide interactions with gene-regulatory and intracellular processes
- Biochemical investigation of defined low-molecular-weight peptide sequences
These areas describe laboratory and experimental research contexts only and do not imply suitability for human or veterinary use or any therapeutic effect.
Storage & Handling
Cartalax is supplied in lyophilised form and should be handled using appropriate laboratory procedures.
Pronoia stock is maintained in temperature-controlled cold storage and organised by identifiable batch prior to dispatch.
Consult the relevant Safety Data Sheet and batch documentation for product-specific storage and handling information. Receiving laboratories should apply their own validated procedures.
Delivery & Documentation
Pronoia uses tracked Royal Mail services and discreet packaging for dispatched orders.
Monday–Thursday: Orders with cleared payment received before 3pm UK time are dispatched the same working day.
Friday: Same-day dispatch is available where the Saturday Guaranteed delivery option is selected and the applicable acceptance cut-off can be met. Standard Friday and weekend orders are held securely in Pronoia’s temperature-controlled storage and dispatched Monday morning.
Temperature-conscious packaging: Available as an optional paid addition.
Tracking information is provided for dispatched orders. COA, SDS and batch-documentation enquiries can normally be fulfilled within 24 hours.
Research Use Statement
For laboratory research use only.
This material is not supplied for human or veterinary use, diagnosis, treatment, prevention of disease or any other therapeutic application. Pronoia does not provide dosage, treatment or administration guidance.
